双歧杆菌等四联活菌治疗小儿腹泻的安全性及有效性探讨

Safety and Effectiveness of Biteobacteria in Pediatric Diarrhea

文章为探讨双歧杆菌等四联活菌治疗小儿腹泻的安全性与有效性,选择汉臣氏(沈阳)儿童制品有限公司在2022年9月—2023年5月收集的120名腹泻患儿志愿者作为研究对象,将其平均分为实验组和对照组,每组各60例。实验组与对照组均接受腹泻的常规补液治疗和食物治疗,另外,对照组服用蒙脱石散,实验组在对照组的基础上增加双歧杆菌等四联活菌。用药后实验组的IL-6、IL-17水平显著低于对照组(P<0.05);实验组的总有效率显著高于对照组(P<0.05);实验组的止泻时间和住院时间均少于对照组,差异具有统计学意义(P<0.05)。用药后实验组的双歧杆菌和乳杆菌数量都明显增长,对照组双歧杆菌和乳杆菌的数量反而呈下降趋势。说明双歧杆菌等四联活菌对于治疗小儿腹泻疗效显著,且安全性较高,是一种安全可靠的临床用药。

In order to explore the safety and effectiveness of bifidobacteria and other four live bacteria in the treatment of infantile diarrhea,120 children with diarrhea volunteers collected by Hansen's(Shenyang)Children's Products Co.,Ltd.from September 2022 to February 2023 were selected as research subjects,and they were divided into an experimental group and a control group,with 60 cases in each group.Both the experimental group and the control group received routine fluid replacement treatment and food treatment for diarrhea.The control group took montmorillonite powder,and the experimental group added bifidobacteria and other four live bacteria on the basis of the control group.(Hanchen)(produced by Hanchen After medication,the levels of IL-6 and IL-17 in the experimental group were significantly lower than those in the control group(P<0.05);The total effective rate of the experimental group was significantly higher than that of the control group(P<0.05);The diarrhea cessation time and hospitalization time of the experimental group were both shorter than those of the control group,and the difference was statistically significant(P<0.05).After medication,the number of bifidobacteria and lactobacilli in the experimental group showed a significant increase,while the number of bifidobacteria and lactobacilli in the control group showed a downward trend.It indicates that bifidobacteria and other quadruple live bacteria have significant therapeutic effects and high safety in the treatment of pediatric diarrhea,making them a safe and reliable clinical medication.